Emtricitabine/Tenofovir — Discount Pricing

Other medications in Infectious Disease

• Glecaprevir/Pibrentasvir
• Levofloxacin
• Molnupiravir
• Nirmatrelvir/Ritonavir
• Nitrofurantoin
• Sofosbuvir/Velpatasvir
• Trimethoprim
• Amoxicillin

About Emtricitabine/Tenofovir

Emtricitabine tenofovir is a powerful combination medication primarily used in two critical areas: the treatment of Human Immunodeficiency Virus (HIV) infection and as pre-exposure prophylaxis (PrEP) to prevent HIV in individuals at high risk. It is also used as part of post-exposure prophylaxis (PEP) regimens after potential exposure to HIV.

What Emtricitabine Tenofovir Treats

When used for HIV treatment, emtricitabine tenofovir is typically prescribed as part of a multi-drug regimen to suppress the virus, reduce viral load, and improve the immune system's health. For PrEP, it’s taken daily by HIV-negative individuals to significantly lower their risk of acquiring HIV from sexual activity or injection drug use. This medication is a cornerstone in global efforts to control and prevent the spread of HIV.

How It Works

This medication combines two distinct antiviral drugs: emtricitabine and tenofovir. Both are nucleoside reverse transcriptase inhibitors (NRTIs). They work by blocking an enzyme called reverse transcriptase, which HIV needs to replicate itself and spread within the body. By inhibiting this enzyme, emtricitabine tenofovir effectively reduces the amount of HIV in the blood, helping to protect the immune system or prevent the virus from establishing an infection in the first place.

Typical Costs of Emtricitabine Tenofovir

Without insurance or discount programs, the cost of emtricitabine tenofovir can be substantial. Brand-name versions

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Emtricitabine/Tenofovir is approved for (FDA label)

HIV-1 Treatment ( 1.1 ) Emtricitabine and Tenofovir Disoproxil Fumarate Tablets is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated: • in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg. HIV-1 PrEP ( 1.2 ): • Emtricitabine and Tenofovir Disoproxil Fumarate is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Source: Read the full FDA label on DailyMed. Label effective date: August 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Emtricitabine/Tenofovir (FDA label)

WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued emtricitabine and tenofovir disoproxil fumarate tablets. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue emtricitabine and tenofovir disoproxil fumarate tablets. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions ( 5.1 )]. Emtricitabine and tenofovir disoproxil fumarate tablets used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP following undetected acute HIV-1 infection. Do not initiate Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP if signs or symptoms of acute HIV-1 infection are present unless negative infection status is confirmed [see Warnings and Precautions ( 5.2 )]. WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION See full prescribing information for complete boxed warning.

Source: FDA prescribing information (DailyMed). Set ID: 41bd03ea-b92e-459c-968b-c9095ae90aef. SPL document ID: 191b8386-d343-471e-9a9c-101b4857c675. Label effective date: August 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Emtricitabine/Tenofovir (FDA label)

Emtricitabine and tenofovir disoproxil fumarate are available in single dose strength: • Tablet: 200 mg of emtricitabine and 300 mg of tenofovir DF (equivalent to 245 mg of tenofovir disoproxil): white, capsule shaped, film-coated tablets, debossed with “L-24” on one side and plain on the other surface. Tablets: 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate. (3)

Source: FDA prescribing information (DailyMed). Set ID: 41bd03ea-b92e-459c-968b-c9095ae90aef. SPL document ID: 191b8386-d343-471e-9a9c-101b4857c675. Label effective date: August 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Emtricitabine/Tenofovir (FDA label)

The following adverse reactions are discussed in other sections of the labeling: • Severe Acute Exacerbations of Hepatitis B in Patients with HBV Infection [ see Warnings and Precautions ( 5.1 )]. • New Onset or Worsening Renal Impairment [ see Warnings and Precautions ( 5.3 )]. • Immune Reconstitution Syndrome [ see Warnings and Precautions ( 5.4 )]. • Bone Loss and Mineralization Defects [ see Warnings and Precautions ( 5.5 )]. • Lactic Acidosis/Severe Hepatomegaly with Steatosis [ see Warnings and Precautions ( 5.6 )]. • In HIV-1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. ( 6.1 ) • In HIV-1 uninfected adults in PrEP trials, adverse reactions that were reported by more than 2% of emtricitabine and tenofovir disoproxil fumarate tablets participants and more frequently than by placebo participants were headache, abdominal pain, and weight decreased. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact NorthStar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 41bd03ea-b92e-459c-968b-c9095ae90aef. SPL document ID: 191b8386-d343-471e-9a9c-101b4857c675. Label effective date: August 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Emtricitabine/Tenofovir (FDA label)

Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP is contraindicated in individuals with unknown or positive HIV-1 status [ see Warnings and Precautions ( 5.2 )]. Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP is contraindicated in individuals with unknown or positive HIV-1 status. (4)

Source: FDA prescribing information (DailyMed). Set ID: 41bd03ea-b92e-459c-968b-c9095ae90aef. SPL document ID: 191b8386-d343-471e-9a9c-101b4857c675. Label effective date: August 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.